|

Anti-PD1 Monoclonal Antibody Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Anti-PD-1 Monoclonal Antibody

Pipeline

Phase 2: 2

Top Sponsors

  • Yuanquan Yang1
  • City of Hope Medical Center1

Indications

  • Cancer2
  • Lung Non-Small Cell Carcinoma1
  • Stage IIIB Lung Cancer AJCC v81
  • Stage IV Lung Cancer AJCC v81
  • Hematopoietic and Lymphatic System Neoplasm1

Goodyear, Arizona1 trial

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

CTCA at Western Regional Medical Center

Phase 2

Columbus, Ohio1 trial

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.